Purpose: To measure plasma 5-fluorouracil (5-FU) levels using high-performance liquid chromatography (HPLC) and compare the findings to the tissue metabolism of 5-FU evaluated using 19F magnetic resonance spectroscopy (MRS), during a protracted venous infusion (PVI) with or without interferon-a.
Introduction
Protracted venous infusion 5-FU at a dose of 300 mg/ mVday was first tested in a phase I study by Lokich et al. [1] . Although no pharmacokinetic analysis was reported initially, several groups have now investigated this regimen, using a variety of analytical methods [2] [3] [4] [5] . On this dose schedule, Spicer et al. [2] found the plasma concentrations of 5-FU were ~1 ng/ml and did not appear to change over a 3-week period. In contrast, however, Sparano et al. [4] detected 5-FU in concentrations of up to 200 ng/ml on the same dose schedule (300 mg/m 2 /day). Meadows et al. [6] have attempted to measure 5-FU during the first 24 hours of the same schedule, but found the levels below 1 ng/ml, their level of sensitivity. Barberi-Heyob et al. [5] have measured a plasma 5-FU concentration of 46 ng/ml, in a sample taken from a patient 8 weeks into a 5-FU infusion of 400 mg/m 2 /day. The discrepancy may be partly explained by a study showing diurnal variation in the activity of plasma dihydropyrimidine dehydrogenase and in plasma 5-FU concentrations, such that peak concentrations of 30 ng/ml are seen at midday and trough levels below 10 ng/ml at midnight [3] . Sampling at different times of the day will therefore yield significantly different results.
The effect of interferon-a on the pharmacokinetics of 5-FU has been studied using several different 5-FU schedules. Schuller et al. [7] found an 80% increase in the 5-FU AUC following an intravenous bolus injec-tion of 750 mg/m 2 . In another study [8] , the increase in 5-FU AUC was found to be dependent on the dose of interferon administered, with effects seen only with doses of 5 or 10 x 10 6 IU/mVday given with bolus 5-FU (370-425 mg/m 2 ). Conversely, using a 5-FU infusion (750 mg/m 2 for 5 days) with various doses of interferon-a, Danhauser et al. [9] , found a dose-independent effect of interferon-a on intra-patient 5-FU steady state concentrations and clearance. With the same 5-FU schedule, however, Pittman et al. [10] could find no alteration in the 5-FU pharmacokinetics. Investigation of interferon-a effects on protracted venous infusion 5-FU at a dose of 300 mg/m 2 /day has been reported by two groups [4, 6] . In the first study, blood was sampled before and after the administration of interferon-a which was commenced 24 hours after the start of the 5-FU infusion [6] . A greater than 16-fold increase in the 5-FU concentration was observed, however, in a more recent study [4] , no differences in the 5-FU pharmacokinetics were noted when interferon-a was added after 48 hours of the 5-FU infusion, although plasma levels of up to 400 ng/ml were documented. There is therefore still uncertainty as to the effects of interferon-a on protracted venous infusions.
Using in vivo 19F-magnetic resonance spectroscopy (MRS), a novel method of non-invasive investigation of 5-FU pharmacology, we have studied the metabolism and distribution of this drug in normal liver and tumour tissues of patients both before and after the addition of interferon-a. The results of these investigations are reported elsewhere [11, 12] . In summary this method was able to detect a signal from 5-FU in tumour which correlated with subsequent tumour response, and a signal from 5-FU in normal liver which was associated with absence of 5-FU related toxicities, when patients were receiving 5-FU as a protracted venous infusion. The addition of interferon-a to the 5-FU in these patients was associated with an increase in the 5-FU signals detected in both normal liver and tumour, with the latter associated with ongoing tumour responsiveness. Based on calculated sensitivity levels of this method, the ability to observe signal in these tissues suggests the concentration of 5-FU is in excess of 5 mM, where established plasma levels at least in the early phases of a PVI of 5-FU are in the nM range [13] .
The aim of this study was to further investigate the relationships between the MRS findings and plasma 5-FU levels measured using a reverse-phase ion-pairing HPLC method developed for this purpose. These observations were compared with the clinical outcomes of patient toxicity and tumour response.
Patients and methods

Patient population
Plasma samples for 5-FU analysis were taken from 16 patients enrolled in a phase II study [14), 10 during the single agent PVI 5-FU phase and 9 at the point of refractory tumour before and after the addition of interferon-a. Another 20 patients from a randomised trial [15) (9 on PVI 5-FU alone and 11 on PVI 5-FU plus interferon-a), had plasma taken for evaluation. Because of the limited number of patients with both MRS and plasma 5-FU analysis the data from these two studies has been combined, where appropriate, for example the logistic regression analysis of paired MRS -plasma data sets. Patients were required to give informed consent before being studied. Approval for the study was obtained from the Royal Marsden Hospital Ethical Review Committee.
Chemotherapy regimens
In the first study, PVI 5-FU (300 mg/mVday) was used until the tumour had become refractory to treatment, at which time interferon-a (5 million units three times a week s.c), was added (14] . Dose modification of 5-FU prior to commencement of interferon-a, may have been necessary because of toxicity, however the aim was to examine the change in steady state plasma 5-FU levels with this addition. Some patients in this study also had plasma samples taken over the first weeks of the 5-FU infusion prior to any dose reductions. The data from this group were examined in conjunction with those from the randomised study [15] . Patients from the randomised study had plasma samples taken and MRS performed in order to examine the differences between patients receiving PVI 5-FU and those having additional interferon-a from the outset of treatment. Chemotherapy was administered through an indwelling central venous catheter which had its tip placed in the superior vena cava. A battery-powered ambulatory pump (Lnfumed, Medex (Medifusion), U.S.A.) was used to administer the chemotherapy. A seven day course of 5-FU (300 mg/m 2 /day) was diluted into a 180 ml reservoir bag.
Blood sample collection
Venous blood samples were obtained by peripheral venipuncture, between 9 a.m. and 11 a.m. every two weeks, for eight weeks, unless treatment breaks ensued. Blood was collected into heparinised tubes, kept on ice, and spun promptly, after which the plasma was separated and stored at -20 "C until analysis.
HPLC and sample extraction
The HPLC system consisted of: Waters 510 high-pressure pumps controlled by a Waters automated gradient controller, an automated injector (Perkin Elmer ISS-100, Beaconsfield, Bucks, U.K.) set to inject 150 ul of the sample; a guard column packed on-site with pellicular octadecyl groups bonded to 37-53 urn glass beads (Whatman Ltd., Maidstone, Kent, U.K.); a chromatography column 30 cm length and 0.46 cm internal diameter packed on-site with PS Phase Sep Spherisorb 5 u.m ODS 2 (Phase Separations Ltd., Deeside, U.K.); a Waters 440 absorbance ultraviolet detector using wavelengths of 254 and 280 ran while set at 0.05 absorption units of full scale; and a Kontron Data systems 450 MT2 computerised data acquisition system (Kontron Instruments, Watford, Herts, U.K.). The buffer solution was prepared by adding 200 ul 0.5M tetrabutyl ammonium hydroxide (Fisons Laboratory Supplies, Loughborough, U.K.) to each litre of a 0.02 M solution of KH 2 PO 4 , adjusted to pH 5.9 and degassed. Twenty ml of methanol was added to every litre of this (purified) solution. The buffer was run at 1.0 ml/minute using an isocratic gradient with a run time of 30 minutes.
Standard curves were created with normal human plasma spiked with 5-FU (Sigma Chemical Company, Poole, Dorset, U.K.) at final concentrations ranging from 25 ng/ml to 50 ng/ml. The internal standard, 5-bromouracil (Sigma; 100 ul of 10 ng/ml solution) was added to each 1.5 ml plasma sample. The recovery from the extraction was 45%. Extraction began by adding 75 ul of a 0.1 M sodium hydroxide solution to 1.5 ml of plasma, vortexing, then adding 3 mis of an ethyl acetate/isopropanol (80:20) mixture and vortexing again. The samples were then centrifuged at room temperature at 1500 rpm for 10 minutes. Following this, the tubes were immersed in liquid nitrogen deep enough to freeze the aqueous phase, enabling uncontaminated collection of all available supernatant, which was then evaporated under vacuum (Savant SVC 200H refrigerated speed vacuum pump, Stratech Scientific, Luton, UK.) and later reconstituted in 200 nl of a water/methanol (90:10) mixture. The resultant samples were filtered directly into HPLC tubes using a 0.45 |im pore-size filter (Waters, Millipore Corporation, Watford, Herts, UJC.) attached to a 1 ml syringe, previously flushed with water/methanol (90:10). The HPLC tubes were then capped and ready for analysis.
The retention time for the 5-FU peak was 5.5 ±0.4 min, while that of the 5-bromouracil internal standard was 12.3 ±0.4 min. Based on comparisons with blank plasma and plasma from a patient receiving interferon-a2b alone, there were no peaks co-eluting with 5-fluorouracil or 5-bromouracil. Calibration curves were obtained by plotting the peak area ratio of 5-FU and 5-bromouracil as a function of the spiked 5-FU and an equation derived from the unweighed linear least squares fit of the curves defined by these calibration standards. The regression coefficient for the standard curve was 0.98. The inter-assay variation was <14% and the intra-assay variation 3%-7%. Based on a 20% coefficient of variation, a maximum measurable value for the 5-FU peak size was estimated at 25,000 ng/ml. Plasma 5-FU levels measured above this are thus considered as non-quantifiably high. The lower limit of detection of 5-FU was 25 ng/ml.
Evaluation of plasma 5-FU levels
Because the plasma 5-FU levels were to be used in a comparison with the in vivo MRS studies, which were performed immediately after the plasma was drawn, the intention was to obtain data at times where MRS was likely to be able to observe metabolism. Early pilot experience with MRS in patients on this 5-FU schedule suggested 5-FU metabolism was visible sometimes only after 1-2 weeks following commencement of an infusion (unpublished observations). For this reason plasma was not collected during the first week of the 5-FU infusion, nor was it collected after cessation of the infusion, thus calculation of AUC and clearance values was not possible. Serial plasma levels for a particular patient were plotted against the time on infusion and compared to those of others. Plasma levels were also compared to the same day MRS findings using linear regression.
Statistics
Linear regression analysis was used to compare the levels of plasma 5-FU and the quantitated 19F-MRS signals. The Mann-Whitney test was used to compare the means of the plasma 5-FU levels in those having 5-FU and 5-FU plus interferon-a.
Results
PVI5-FU
A total of 19 patients (14 male; 5 female) had plasma 5-FU data -10 from the phase II study and 9 from the randomised study. The maximum plasma 5-FU levels ranged from <25 ng/ml (0.192 \xM) to >25,000 ng/ml (192 (iM) (see Fig. 1 ). For the purposes of comparison with other variables the group was divided into patients with 5-FU levels > or <650 ng/ml (5 piM). This division falls in a natural break in the spread of the data, with the arbitrary value 5 uM chosen for ease of reference. These plasma concentrations generally represent the steady state levels but because some patients did not have serial samples at a steady state level, the term Cj.pu was used. Several observations can be made based on this division (see Table 1 ). Firstly the incidence of 5-FU related toxicity occurring prior to the elective treatment break at 10 weeks was 8/9 in the high plasma 5-FU group and 5/10 in the low group. Secondly, 7/9 patients who had high 5-FU levels had an abnormal pretreatment serum alkaline phosphatase level, compared to 4/10 in the group with low 5-FU levels. There was, however, no suggestion of a difference in serum alanine aminotransferase, serum bilirubin, or plasma creatinine between the two groups. In the patients with high 5-FU levels 4/8 had a tumour response as did 4 of the 8 with evaluable tumours and
In vivo 19F-MRS
Patients were studied in a 1.5 Tesla Siemens Magnetom whole body magnetic resonance system using a 16 cm diameter transmit/receive surface coil. The coil was placed over either normal liver tissue or over liver metastases that encompassed greater than an estimated 70% of the coil's volume of sensitivity. For patients with liver metastases too small to be studied, where possible, the coil was repositioned to include only normal liver tissue, which was then studied. Using a pulse and collect measurement sequence with an adiabatic half-passage readout pulse and a 2 second repetition time, spectra were acquired for approximately 40 minutes. Each study included a separate measurement of a reference sample. Peaks were assigned on the basis of previously reported resonant frequencies of 5-FU and its metabolites [16] . Because the resonant frequencies of the fluoronucleotides and fluoronucleosides are similar, they cannot be distinguished and are measured collectively. Similarly the major inactive catabolic metabolites of 5-FU, fluroureidoproprionic acid (FUPA) and fluoro-beta-alanine (FBAL) cannot be readily separated and are considered collectively. 5-FU in contrast, has a distinct resonant frequency. Signals were manually integrated and normalised with respect to the reference sample. Peaks were considered for evaluation only if their height was greater than the sum of the baseline and three standard deviations of the background noise. Further details of this method are published elsewhere [17] . 
MRS
Abbreviations: chemo -chemotherapy group; FU -5-FU; FU (n) -5-FU (non-randomised); FU + I -5-FU plus interferon; c i . FV -5-FU plasma concentration (|iM); ALP -serum alkaline phosphatase (normal range 24-110 U/l); bili -serum bilirubin (normal range <17 u.mol/1); ALT -serum alanine aminotransferase (normal range <40 U/l); creat -serum creatinine (normal range 54-116 u.mol/1); PD -progressive disease; PR -partial response; NC -no change; DR -differential response; line out -these 2 patients had central venous line problems (infection, laceration) leading to removal and subsequent replacement (after 7 and 4 days, respectively). MRS -patients who underwent at least one MRS examination for which there is plasma 5-FU data; stom -stomatitis; diarr -diarrhoea; pp -plantar-palmar erythema; inf -infection; conj -conjunctivitis. low levels. Of the 5 female patients, 4 were in the high 5-FU group.
PV15-FU± interferon-a
A total of 11 patients (8 male; 3 female) receiving 5-FU plus interferon-a on the randomised study had plasma evaluated for 5-FU. The detected range of 5-FU in this group was 110 ng/ml (0.85 uM) to >25,000 ng/ml (192 uM) however 10 of the 11 patients had levels in the previously defined high group (>5 uM). Because of patient toxicity this group seldom had more than 1 plasma sample available for 5-FU analysis. When comparing this group to the whole group of 5-FU treated patients (randomised and non-randomised; see Fig. 1 ), it was found that the median 2 week plasma 5-FU levels were 6138 ng/ml (47 uM) with interferon-a and 218 ng/ml (1.68 u.M) with 5-FU alone (p»0.03; Mann-Whitney test). Abnormally raised pretreatment serum alkaline phosphatase levels were seen in 3/11 treated with 5-FU plus interferon-a and 12/19 treated with 5-FU alone. Patient toxicity before the elective treatment break at 10 weeks was seen in 9/11 treated with 5-FU plus interferon-a; however, the two patients with no toxicity had unscheduled 5-FU breaks due to problems with the delivery system, which may have averted impending toxicity. In the 19 patients treated with 5-FU alone there were 13 who had a 5-FU-related toxicity. The incidence of 5-FU-related toxicities in the group of 5-FU plus interferon-a treated patients (8/ 10), was similar to that of the group of patients with high plasma levels of 5-FU treated with 5-FU alone (8/9) . Of the 9 patients with evaluable tumour showing high plasma 5-FU levels while receiving 5-FU plus interferon-a, 4 had a partial response.
Addition of interferon-a to 5-FU
Nine patients (4 male; 5 female) had plasma samples drawn prior to and at weekly intervals for 2 weeks following the addition of interferon-a to an established 5-FU PVI. The results are shown in Table 2 . Four had a The data in this table are from 9 patients (4 with liver metastases; 5 without) who were studied prior to and at 1 and 2 weeks after the addition of interferon [IFN] to 5-FU. The plasma 5-FU concentration is measured in u.M and was noted to increase in 6 of the 9. The 5-FU signal (5-FU sig) and catabolic signal (cat sig), both measured in arbitrary units, did not display any consistent trend with respect to the plasma or the addition of interferon. ND -not done.
logarithmic rise in the 5-FU level, while 3 had at least a 2-fold rise and 2 had no increase in 5-FU levels.
Comparisons with MRS data
A total of 5 patients (4 from the phase II; 1 from the randomised study), had both plasma 5-FU and MRS evaluation of normal liver on a total of 13 different occasions. Using linear regression analysis, a positive correlation was found between liver 5-FU catabolite peak size and the plasma [5-FU] (r -0.6798; p -0.011). A correlation was also found with the log [5-FU] (r = 0.6630; p -0.014). When comparing the plasma to the liver 5-FU peak size there was no correlation (r = -0.4613; p = 0.11); however, using the log plasma [5-FU] a significant inverse correlation was observed (r = -0.6253; p -0.022). There was no apparent relationship between the liver MRS catabolite and 5-FU peak sizes (p -0.12) in these patients, although we have previously documented a significant negative correlation in 14 patients studied with MRS of normal liver (with no plasma 5-FU data) [11] . Two potential confounding factors for this observation, liver function and patient gender, were not able to be examined due to insufficient patient numbers. Of the 5 patients with normal liver MRS data and with 5-FU data, the 3 patients (2 male; 1 female) having no toxicity, had a visible liver 5-FU peak and low plasma 5-FU levels. The other two patients (both female) experiencing toxicity had no liver 5-FU signal but had high plasma 5-FU levels. This is consistent with the MRS findings in the total of 14 patients with normal liver examined previously where a liver 5-FU signal was associated with freedom from toxicity [11] . A total of 3 patients with normal liver received 5-FU plus interferon-a from day one. Although highly significant negative correlations between plasma [5-FU] and both liver MRS 5-FU and catabolite levels (p < 0.0001) were observed, the numbers are too small to be reliable.
The plasma and MRS data on the patients who had interferon-a added at the point of 5-FU refractory disease are presented in Table 2 . Although it is evident that some patients had a significant increase in the plasma [5-FU] after interferon-a was added, there appears to be little consistency between these and the MRS observations. The first patient in this table, who shows an increase in the plasma , was the only patient that had shown an increasing intra-tumoral 5-FU peak size, but no evidence of ongoing rumour responsiveness. The 3 other patients with liver metastases in Table 2 show a variable plasma response to interferon-a addition, but none had an increase in the intra-tumoural 5-FU peak size, nor any evidence of ongoing response. Plasma was not available for analysis on any patients showing on-going response and an increasing tumour 5-FU signal, with the addition of interferon-a.
Tumour MRS evaluation with plasma 5-FU data was available on a total of 22 occasions in 9 patients (4 randomised; 5 not). Comparison of the tumour 5-FU peak size to both the plasma 
Discussion
An unexpected finding in this study was that some of the plasma 5-FU levels were substantially higher than previously documented in the literature. The earliest pharmacological study in patients receiving PVI 5-FU at doses of 200-400 mg/mVday [2] used the sensitive Buckpitt and Boyd method of analysis [15] and found that the mean plasma 5-FU levels out to the third week of the infusion were less than 2 ng/ml. Using a modification of the same method, Sparano et al. [4] found steady state 5-FU levels of up to 200 ng/ml in the first 48 hours of an infusion, in addition to noting a diurnal variation in these levels. Although there is no significant previous experience with plasma levels at 8 weeks we had not anticipated either the magnitude of the values nor the wide interpatient differences. We considered several factors that may explain the findings: firstly the blood was drawn from a peripheral vein so there was no chance of contamination of the blood from the 5-FU which was administered via the central line; the blood was processed according to the stated protocol; the analytical method initially used was a non ion-pairing technique. However, because of the unusually high levels seen in early samples and concern about the level of sensitivity we considered necessary, we questioned the method. We subsequently developed an ion-pairing HPLC method (reported in the study) to both obtain better sensitivity and validate the high plasma 5-FU findings, both of which were achieved. Another issue, which we had not considered until a report by Etienne et al. [19] , was that the pump delivery system was not delivering a genuine continuous infusion but a series of boluses, thus may be causing the relatively high plasma 5-FU levels we observed. They, however, performed their study on 5-FU infusions of 1000 mg/m 2 /day, concluding that this dose in 100 ml diluent (10 mg/m 2 /ml) given every 24 hours was dilute enough to avoid 5-FU levels varying considerably from those with pumps that were genuinely continuous. In our study we were using a dose of 300 mg/mVday diluted in 180 ml over 7 days (2100 mg/m 2 in 180 mis; 11.7 mg/m 2 /ml), which is slightly more concentrated than their stated recommendations, thus could explain the high 5-FU levels. Despite this, however, the serial plasma 5-FU levels for any individual did not appear to change significantly. On the assumption that plasma samples were drawn randomly with respect to the infusion pump injection cycle, during a standardised part of the day, then it is unlikely that such consistent plasma levels would be seen (as depicted in Fig. 1 ).
When considering the inter-patient variation in plasma 5-FU levels, two potential contributing factors we noted were female gender, documented recently in 5-day 5-FU infusions by Milano et al. [20] , and the pretreatment serum alkaline phosphatase. In a study of the diurnal variation in 5-FU and dihydropyrimidine dehydrogenase levels, however, Harris et al. [3] examined 7 patients over the first 2 days of a 300 mg/ m 2 /day infusion. Three of the patients had raised alkaline phosphatase levels, yet their maximum 5-FU level was 38 ng/ml, and no different to those with normal levels. Spicer et al. [2] measured 5-FU at <2 ng/ml out to 3 weeks of the infusion; however, they did not specify the patient gender or pre-treatment alkaline phosphatase status. The high plasma 5-FU levels appeared to be associated with a higher incidence of patient toxicity than in those with lower levels, although not all patients developed toxicity before the elective break at 10 weeks. This observation lends weight to the plasma findings; however, these associations would need further evaluation with greater patient numbers.
The impact of interferon-a on plasma 5-FU levels was evaluated in two clinical settings. The first was where it was added to the infusion at a point of 5-FU refractory disease and the second was in the randomised trial. From the phase II study, 9 patients were evaluated, with 4 showing a logarithmic increase in the 5-FU levels and 3, a greater than 2-fold rise over a subsequent 2-week period. The findings in the randomised study are consistent with these observations with the significantly higher plasma 5-FU levels at 2 weeks of the infusion in the interferon-a treated group. These results suggest interferon-a does have some impact on 5-FU clearance when administered on this schedule.
The comparison of the MRS data with the plasma data, despite relatively small patient numbers, yields several interesting observations. Quantification of MRS data remains a difficult problem; however, based on the study by Schlemmer et al. [13] , it is unlikely that 5-FU will be detectable in vivo with MRS at tissue concentrations <5 mM. The maximum quantifiable plasma 5-FU concentration in this study is 192 (iM so will not be detected by MRS; however, it is clear that signals are detectable in both liver and tumour, indicating a concentrating effect in these tissues. A study by Peters et al. [21] , using tumour biopsy analysis following a 5-FU bolus, demonstrated a one log higher concentration of 5-FU in the tumour and normal tissue, compared to the plasma level. Their observation would be consistent with the findings in this study.
Sequential assessment of normal liver using MRS in patients on 5-FU, when combined with their plasma 5-FU data showed that two patients who got toxicity had high plasma 5-FU concentrations, no visible liver 5-FU signal and higher liver catabolite signal.
Conversely the 3 patients with no toxicity had low plasma 5-FU concentrations, had liver 5-FU signals and had lower liver catabolite signals. The finding that the plasma 5-FU concentration is positively correlated with the 5-FU catabolite peak size in liver tissue is not unexpected; however, the observed negative correlations between plasma 5-FU and liver MRS 5-FU signal size, and between the MRS signals from 5-FU and catabolites, cannot be explained unless a feedback control on the liver uptake of 5-FU by its catabolites was postulated. In addition, the observed correlation between liver 5-FU signal and freedom from toxicity is supported by the finding that those with high plasma 5-FU levels appear to suffer toxicity more frequently.
In the patients with liver metastases it was not possible to detect any association between plasma 5-FU concentration and tumour MRS 5-FU signal size. Coupled with the lack of significant correlation between plasma 5-FU concentration and tumour response, plus our previous observation that a 5-FU signal in tumour predicts response, the importance of the intra-tumoural 5-FU levels is evident. These findings, however, could be the result of either or both of two important factors: the small size of the sample in the investigation; and, more importantly for planning further studies with this methodology, is that sequential measurements of the signal size from a tumour may vary with inconsistent repositioning of the surface coil and with changes in the size of the lesion being examined, as a function of the percent of the coil's volume of sensitivity. Other investigators, however, using tissue biopsy specimens, found no correlation between plasma 5-FU and tissue 5-FU levels [22, 23] .
The results of this pilot experience, we believe raise some interesting questions about the administration and monitoring of 5-FU on a protracted venous schedule. In particular the use of MRS has enabled non-invasive and repeated assessment of 5-FU metabolism and its modulation offering information complementary to conventional plasma 5-FU data. Until confirmed by larger studies, however, the results should be interpreted with some caution.
